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To assess the usefulness of procalcitonin, pro-adrenomedullin and pro-atrial natriuretic pep-
tide as predictors of need for mechanical ventilation and postoperative complications (need
for inotropic support and bacterial infection) in critically ill pediatric patients after cardiopul-
monary bypass.
Design
A prospective, observational study
Setting
Pediatric intensive care unit.
Patients
Patients under 18 years old admitted after cardiopulmonary bypass.
Measuraments and main results
Serum levels of procalcitonin, pro-adrenomedullin and pro-atrial natriuretic peptide were
determined immediately after bypass and at 24–36 hours. Their values were correlated with
the need for mechanical ventilation, inotropic support and bacterial infection. One hundred
eleven patients were recruited. Septal defects (30.6%) and cardiac valve disease (17.1%)
were the most frequent pathologies. 40.7% required mechanical ventilation, 94.6% inotropic
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support and 15.3% presented invasive bacterial infections. Pro-adrenomedullin and pro-
atrial natriuretic peptide showed significant high values in patients needing mechanical ven-
tilation. Cut-off values higher than 1.22 nmol/L and 215.3 pmol/L, respectively for each bio-
marker, may indicate need for mechanical ventilation with an AUC of 0.721 and 0.746 at
admission and 0.738 and 0.753 at 24–36 hours, respectively but without statistical differ-
ences. Pro-adrenomedullin and procalcitonin showed statistically significant high values in
patients with bacterial infections.
Conclusions
After bypass, pro-adrenomedullin and pro-atrial natriuretic peptide are suitable biomarkers
to predict the need for mechanical ventilation. Physicians should be alert if the values of
these markers are high so as not to progress to early extubation. Procalcitonin is useful for
predicting bacterial infection. This is a preliminary study and more clinical studies should be
done to confirm the value of pro-adrenomedullin and pro-atrial natriuretic peptide as bio-
markers after cardiopulmonary bypass.
Introduction
Procalcitonin (PCT), pro-adrenomedullin (pro-ADM) and brain natriuretic peptide have
been proposed as useful biomarkers for therapeutic decision-making in patients that require
cardiopulmonary bypass (CPB), at both pre-and post-surgical time [1–5]. Recent studies
underlined the promising utility of them as prognostic predictors in patients with heart failure
or low cardiac output syndrome also in children [6–9]. PCT is known to be more specific and
earlier than classical biomarkers in the diagnosis of infectious complications [10,11]. Although
PCT may increase slightly in the systemic inflammatory response syndrome, as it occurs after
CPB, most studies point to better predictive values of PCT than other clinical or analytical
markers to discriminate the presence or absence of infection [6,12–14]. Other biomarkers
such as pro-ADM and pro-atrial natriuretic peptide (pro-ANP) would be more appropriate in
the stratification of the severity of critically-ill patients. These biomarkers can be even better
prognostic markers than the traditional severity scores such as the Pediatric Risk Score Mortal-
ity III (PRISM III) [15–17]. Adrenomedullin is a potent vasodilator that can act as a hormone
or cytokine and plays a role in controlling pulmonary flow, migration of leukocytes and elec-
trolyte balance. Pro-ADM is a peptide directly measuring the blood levels of adrenomedullin,
but biochemically more stable and easier to determine. Several studies have shown the useful-
ness of pro-ADM as a marker of severity and prognosis in patients with respiratory infections,
and sepsis [18–20]. Some studies have described increased levels of adrenomedullin after CPB,
thus it could be useful in the post-operatory [21,22]. A more recent study has shown that pro-
ADM could accurately detect pediatric heart failure [7]. The brain natriuretic peptide and the
pro-ANP have been proposed as markers of heart dysfunction, and as prognostic markers for
monitoring patients with heart failure, acute coronary syndromes and hypertension [7,8,23–
25]. There are many publications about the usefulness of brain natriuretic peptide in children
[26], but not about pro-ANP. An increase of pro-ANP has been described in septic patients,
and its usefulness as a prognostic marker in the CPB has also been suggested [27,28].
As far as we know, the studies linking these biomarkers and cardiac pathologies are basi-
cally oriented to describe their levels in cardiac failure and, in a lesser extent, cardiac surgery.
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In any case, these studies are scarce and tackle different heart diseases. In children, the number
of studies is even lower and there are no clear conclusions that could be helpful in clinical prac-
tice. One of the main concerns when managing patients with CPB is to predict mortality and
morbidity to anticipate its handling. Morbidity in patients after CPB was classically considered
as the length of stay (LOS), but intensive support requirements after CPB could be also inter-
esting to be determined as morbidity. Our aims in this investigation were to assess in criti-
cally-ill patients after CPB: i) PCT, pro-ADM and pro-ANP levels in the first 36 hours post-
CPB; ii) the prognostic usefulness of these biomarkers comparing with PRISM III, regarding
the need for respiratory and hemodynamic supports, and LOS after CPB and iii) the usefulness
of these biomarkers as predictors of bacterial infection.
Materials and methods
A prospective and observational study (July 2012-October 2013) was conducted on patients
attended in the Pediatric Intensive Care Unit (PICU) of a tertiary-care children’s hospital with
345 beds (18 PICU beds). Referral population: Catalonia, with ~7 million population and 1.2
million children under 18 years, this captured around 17% of all pediatric hospital admissions
during the study period. The study was approved by the ethics committee of the hospital
(CEIm Fundacion Sant Joan de Deu, Barcelona) and the institutional review board. Written
informed consent was obtained from parents or the legal guardian of each child.
The inclusion criteria were patients admitted at PICU after CPB, aged between 1 month
and 16 years, and who provided signed informed consent. Exclusion criteria were underlying
disease (rheumatologic, systemic) and presence of primary or secondary immunodeficiency.
Serum levels of PCT and the mild regional peptide segment of the prohormones pro-ADM
and pro-ANP [29,30] were determined by immunofluorescence by means of a Time-Resolved
Amplified Cryptate Emission (TRACE) and a Kryptor analizer (B�R�A�H�M�S-Diagnostica
GmbH, Henningsdorf, Germany). Limit detection values were 0.06 ng/mL for PCT, 0.23
nmol/L for pro-ADM, and 2.1 pmol/L for pro-ANP. Values were considered normal for a
PCT value < 0.5 ng/ml, a pro-ADM value < 0.5 nmol/L, and pro-ANP value < 70 pmol/L.
The three biomarkers were collected from the same blood sample (1 ml). Sampling times were
immediately post-CPB (post-CPB1), and between the 24–36 hours post-CPB (post-CPB2).
The clinicians were blinded to the biomarkers results during the investigation.
The clinical parameters recorded were age; gener; type of heart disease; surgery time includ-
ing surgery total time, bypass time and cross clamp time; ultrafiltrate volume; surgery com-
plexity assessed with STS-EACTS score [31], and patient severity by PRISM III. Morbidity was
evaluated through the need for mechanical ventilation (MV) at PICU admission and at 48
hours, use of inotropes at admission, presence of renal failure, invasive bacterial infection (IBI)
complication (sepsis, pneumonia, urinary tract infection, meningitis) and PICU LOS; Mortal-
ity was also registered. In case of suspected infection, cultures of the different biological sam-
ples were processed: blood sample, urinary culture, and tracheal aspirate or broncho alveolar
lavage. Pneumonia was suspected due to clinical data (fever > 38˚C, tachypnea, respiratory
worsening), thorax X ray with persistent infiltrates and C reactive protein > 70 mg/L. IBI was
confirmed by positive cultures. Sepsis diagnosis was defined according to the local protocol
(positive culture and life-threatening organ dysfunction [32]). Diagnosis of nosocomial infec-
tion was performed according to the criteria of the Centre for Disease Control and Prevention
[33].
Sample characteristics were expressed as counts and percentage for categorical variables, as
mean ± standard deviations for normal continuous variables, or as a median and interquartile
range (IQR) for non-parametric data. Differences in PCT, pro-ADM and pro-ANP values
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were compared according to the morbidity and mortality data, by student T test or Mann-
Whitney U test. The correlation of time of MV and pro-ADM were assessed using Pearson’s
correlation. To compare the predictive value of PCT, pro-ADM, and pro-ANP, receiver-oper-
ating characteristic (ROC) curves and the area under the curve (AUC) were assessed. Prognos-
tic parameters such as cut-off, sensitivity, specificity, positive and negative predictive values
were calculated. Mean of PRISM III punctuation was correlated with PCT, pro-ADM and pro-
ANP levels at admittance by means of a linear regression analysis. All tests were two-tailed.




One hundred and eleven patients were included in the study, the 53.1% were males, and the
median age was 26 months (IQR 7 months—6.5 years). Heart disease diagnoses were: 34 septal
defects (30.6%), 19 cardiac valve disease (17.1%), 13 atrioventricular canal defect (11.7%), 12
Fallot tetralogy (10.8%), 6 single ventricle (5.4%), 3 transposition of the great arteries (2.7%)
and 14 other heart disease (12.6%). Mean surgery total time, bypass time and cross clamp time
were: 150 minutes (IQR 125–190), 70 minutes (IQR 54–95) and 41 minutes (IQR 28.50–66).
Median PRISM III score was 3 points (IQR 3–5). The most frequent STAT mortality category
was category 2 (48, 43.2%).
At admission, a total of 48 patients (40.7%) required MV whereas the rest were extubated at
operating room. The median days of MV were 0 days (IQR 0–2). Inotropic support with milri-
none was required in 105 patients (94.6%), and 34 patients (30.6%) required milrinone with
any other inotropic drug (dopamine or epinephrine). Complications due to IBI were diag-
nosed in 15.3% of patients, with a final diagnosis of sepsis (47.1%) and pneumonia (29.4%) as
the main causes of infection. Renal failure was not detected in any patient. One patient died at
72 hours.
Biomarker levels
The median levels of the different biomarkers were at post-CPB1: for PCT 0.31 ng/ml (IQR
0.07–1.04); for pro-ADM 1.03 nmol/L (IQR 0.79–1.49); and for pro-ANP 174.90 pmol/L (IQR
106.60–339.40). Results at post CBP2 were: PCT 0.73 ng/ml (IQR 0.34–2.60); pro-ADM 1.13
nmol/L (IQR 0.81–1.83); and pro-ANP 147.10 pmol/L (IQR 95.16–285.70). Correlation values
of the three biomarkers and several cardiac surgery characteristics are summarized in supple-
mentary material 1. At post-CPB1, both pro-ADM and pro-ANP showed a significant positive
correlation with bypass time and cross clamp time, and a significant negative correlation with
ultrafiltrate. Pro-ADM also showed a significant correlation with surgery total time and PCT
did not show any significant correlation. PRISM III value failed to demonstrate a significant
correlation neither with surgery time nor with ultrafiltrate.
Biomarkers and intensive support in PICU
The comparison between biomarker levels according to MV, IS and IBI are recorded in
Table 1. Pro-ADM and PRO-ANP showed significantly higher values in those patients requir-
ing MV or inotropic support with two drugs at post-CPB1 and post-CPB2. Pro-ADM at post-
CPB1 and post-CPB2 presented positive correlations with the number of days of MV
(r = 0.643 at post-CPB1 and r = 0.798 at post-CPB2, with p<0.001). Also PRO-ANP showed
positive correlations with the days of MV (r = 0.557 at post-CPB1 and r = 0.631 at post-CPB2,
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with p<0.001). PCT values did not show significant differences in these comparisons. PCT
and pro-ADM showed significant higher values in patients with IBI, both at post-CPB1 and
post-CPB2 whereas PRO-ANP only showed significant higher values at post-CPB2. The evolu-
tion of the median levels of biomarkers regarding MV requirement for pro-ADM and
PRO-ANP, or IBI complication for PCT is represented in Fig 1.
Table 1. Biomarkers levels at post-CPB1 and post-CPB2 according to mechanical ventilation, inotropic support and invasive bacterial infection. Data expressed by
median (interquartile range) and compared with Mann-Whitney test.
post-CPB1 post-CPB2
Biomarker levels MV n = 48 Non-MV n = 63 p-value MV n = 38 Non-MV n = 73 p-value
PCT (ng/ml) 0.37 (0.06–1.20) 0.26 (0.09–0.80) 0.782 0.23 (0.06–1.16) 0.34 (0.13–0.88) 0.580
Pro-ADM (nmol/L) 1.35 (0.99–2.02) 0.92 (0.73–1.16) 0.000 1.34 (0.98–1.94) 0.91 (0.75–1.15) 0.000
Pro-ANP (pmol/L) 299.80 (147.10–476.58) 124.50 (89.25–230.05) 0.000 301.02 (144.95–464.45) 124.50 (86.97–221.30) 0.000
Biomarker levels Inotropic support
n = 34
Non-inotropic support n = 77 p-value Inotropic support n = 28 Non-inotropic support n = 83 p-value
PCT (ng/ml) 0.42 (0.07–3.10) 0.28 (0.23–0.79) 0.283 0.38 (0.70–2.68) 0.31 (0.66–0.80) 0.590
Pro-ADM (nmol/L) 1.36 (0.99–2.69) 0.96 (0.74–1.27) 0.000 1.50 (1.03–2.70) 0.96 (0.74–1.25) 0.000







Non-IBI n = 94 p-value
PCT (ng/ml) 1.98 (0.275–5.53) 0.23 (0.07–0.75) 0.020 3.89 (2.03–6.00) 0.41 (0.071–0.63) 0.000
Pro-ADM (nmol/L) 1.44 (0.94–2.21) 1 (0.78–1.45) 0.036 1.84 (1.23–2.68) 0.95 (0.75–1.15) 0.000
Pro-ANP (pmol/L) 186.10 (137.70–350.02) 174.90 (104.55–341.30) 0.502 244.20 (138.95–507.7) 148.80 (92.97–326.05) 0.000
MV: mechanical ventilation, IBI: invasive bacterial infection, PCT: procalcitonin, pro-ADM: pro-adrenomedulin, Pro-ANP: pro-atrial natriuretic peptide, CPB:
cardiopulmonary bypass.
https://doi.org/10.1371/journal.pone.0215690.t001
Fig 1. Evolution of the median levels of pro-adrenomedullin (plot a) and pro-atrial natriuretic peptide (plot b)
regarding mechanical ventilation (MV); and procalcitonin (plot c) regarding invasive bacterial infection (IBI) at
pre and post cardiopulmonary bypass (CPB). Values of pro-adrenomedullin (pro-ADM) expressed as nmol/L, pro-
atrial natriuretic peptide (ANP) as pmol/L, values of procalcitonin (PCT) expressed as ng/mL.
https://doi.org/10.1371/journal.pone.0215690.g001
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Surgery times were significantly higher in patients with MV: Surgery total times were 170
minutes (IQR 140–235) vs. 138.5 (IQR 116.25–163.75), p = 0.000; bypass time 90 minutes
(IQR 67–135) vs. 59.5 (IQR 47.25–77.75), p = 0.000; and cross clamp time 55 minutes (IQR
39.5–83.5) vs. 34.5 (IQR 22.5–77.45), p = 0.006. There were no statistical differences regarding
ultrafiltrate. None of these surgery times showed significant differences either with inotropic
support requirement or with IBI complications.
At post-CPB1, PRISM III showed significant higher values in patients with MV (score of 3,
IQR 2–7) than in patients that do not required MV (score of 2, IQR 2–5). No statistical differ-
ences between PRISM III and MV were detected at post-CPB2. Similarly, PRISM III failed to
show significant differences between patients according to inotropic support requirement or
IBI complications.
Given the significant results of pro-ADM and pro-ANP regarding MV requirement, the
cut-off points of these two markers were analyzed and are summarized in Table 2. Although
pro-ANP showed slightly higher AUC values than pro-ADM at post-CPB1 (0.746 vs. 0.721)
and post-CPB2 (0.753 vs. 0.738), no significant differences between AUCs for pro-ANP and
pro-ADM were found. AUC for PRISM III to predict MV at post-CPB1 was 0.60 (CI95%
0.497–0.697; p = 0.0749) and the optimal cut-off was up to 2 points. The AUCs for pro-ADM
and pro-ANP were considerably higher than the AUC for PRISM III but only the comparison
between pro-ADM and PRISM III AUCs was statistically significant (p = 0.034). The AUC for
bypass time and cross clamp time were higher to predict MV after CPB, than the surgical time
and the ultrafiltrate volume (Table 2).
When IBI was diagnosed, PCT, pro-ADM and pro-ANP levels were increased at both post-
CPB1 and post-CPB2 (Table 1). The AUCs of the three biomarkers for this complication are
reported in Table 3 and plotted in Fig 2. At post-CPB1, the AUC for pro-ADM (0.726) was
Table 2. Area under the curve for pro-ADM and pro-ANP measured at post-CPB1 and post-CPB2, and PRISM III value at post-CPB1 with regard to mechanical
ventilation requirement.
Mechanical ventilation requirement








Pro-ADM CPB1 0.721 0.006
(0.568–0.845)





Pro-ANP CPB1 0.746 0.002
(0.589–0.881)
> 215.3 69.55 (32.20–75.63) 78.26 (56.35–92.55) 70.87
(46.61–88.69)
77.16 (57.07–90.98)






















































64.81 (50.68–77.35) 51.85 (27.57–75.51) 82.16 (58.04–95.63)









MV: mechanical ventilation, CPB: cardiopulmonary bypass, pro-ADM: pro-adrenomedullin, pro-ANP: pro-atrial natriuretic peptide, PRISM III: Pediatric Risk Score
Mortality III, AUC: area under the curve, CI: confidence interval, Sn: sensitivity, Sp: specificity, PPV: positive predictive value, NPV: negative predictive value.
https://doi.org/10.1371/journal.pone.0215690.t002
Usefulness of pro-adrenomedullin and other biomarkers after cardiopulmonary bypass in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0215690 June 17, 2019 6 / 12
higher than the AUCs for PCT (0.643) and pro-ANP (0.622). At post-CPB2, the biomarker
with the highest AUC was PCT (0.896) followed by pro-ADM (0.795) and pro-ANP (0.722).
When the AUCs between biomarkers were compared two by two, the only significant differ-
ence was found between PCT and pro-ADM at post-CPB2 (p = 0.013, plot c in Fig 2).
Biomarker levels according to PICU LOS are reported in Table 4. As expected, levels were
higher in those patients with more days of PICU stay but only the differences for pro-ADM
and pro-ANP were statistically significant.
Discussion
This study provides important information on the values of three biomarkers during the first
36 hours post-CPB. The results obtained underline for the first time the prognostic usefulness
of pro-ADM and pro-ANP to predict need for prolonged MV and LOS after CPB on one
hand, and confirm the value of the PCT to predict the infectious complication. The three bio-
markers showed persistently high values in those patients that needed MV or inotropic sup-
port after surgery, but only the results of pro-ADM and pro-ANP were statistically significant
Table 3. Area under the curve (AUC) for the three biomarkers with respect to the presence of invasive bacterial infection. Data expressed by median (interquartile
rang).
post-CPB1
Biomarker AUC p (CI 95%) Cut off Sn % (CI 95%) Sp % (CI 95%) PPV (%) NPV (%)
PCT (ng/ml) 0.643 0.017
(0.549–0.729)




Pro-ADM (nmol/L) 0.726 <0.001
(0.633–0.806)
> 0.90 80.95 (65.9–91.4) 47.83 (35.6–60.2) 21.89 (2.70–59.69) 93.29
(50.43–99.99)
Pro-ANP (pmol/L) 0.622 0.023
(0.525–0.712)





Biomarker AUC p (CI 95%) Cut off Sn % (CI 95%) Sp % (CI 95%) PPV (%) NPV (%)
PCT (ng/ml) 0.896 0.001
(0.821–0.947)




Pro-ADM (nmol/L) 0.795 <0.001
(0.701–0.870)




Pro-ANP (pmol/L) 0.727 < 0.001
(0.627–0.812)




CPB: cardiopulmonary bypass, AUC: area under the curve, CI: confidence interval, Sn: sensibility, Sp: specificity, PPV: positive predictive value, NPV: negative
predictive value, PCT: procalcitonin, pro-ADM: pro-adrenomedullin, Pro-ANP: pro-atrial natriuretic peptide.
https://doi.org/10.1371/journal.pone.0215690.t003
Fig 2. Areas under the curve for procalcitonin, pro-adrenomedullin and pro-atrial natriuretic peptide at post-CPB1
(plot a), at post-CPB2 (plot b). Plot c represents area under the curve for procalcitonin and pro-adrenomedullin at
post-CPB2 (plot c).
https://doi.org/10.1371/journal.pone.0215690.g002
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at both times of the analysis. Pro-ADM and pro-ANP can be analysed with the same test in a
few minutes (30–60 minutes), which provides valuable information for clinicians. In those
patients with bacterial infection, pro-ADM and PCT showed statistically significant high val-
ues at post-CPB1 and post-CPB2. This finding could be due to the fact that pro-ADM and
pro-ANP have a more important role in vasoregulation than PCT, which seems to be mainly
activated by an infectious stimulus. During CPB there is a syndrome of systemic anti-inflam-
matory response with pathophysiological changes affecting homeostasis. There is an activation
of the renin-aldosterone system increasing vascular resistances, diminishing urinary volume
and presenting a third space due to fluid retention [34,35]. These changes may induce an
increased production of ADM and pro-ANP to counteract the effects above mentioned and
protect the heart muscle.
With regard to ADM and ANP, some studies demonstrated the progressive increasing of
these biomarkers and their vasoregulatory role in CPB [35,36]. Our results are similar to those
of Brancaccio and collaborators [37] in adults, describing an increase of ANP after CPB in
response to the hypothermia and ischemia with an effect of myocardial protection. Nagata
et al. described a correlation between cross clamp time and increase of ADM in 10 adults
undergoing CPB [38]. The correlation between cross clamp time and increase of ADM sug-
gests a vasodilator effect at coronary level to avoid ischemia. Szekely et al. showed that high lev-
els of preoperative ADM are associated with less myocardial damage underlining the
regulatory role of ADM in coronary flow both in ischemia and basal conditions [22]. The
study of Hiramatsu showed an increase of ANP after Fontan procedure suggesting that ANP
plays a mechanism of control of body fluids avoiding ascites and massive pleural effusion [39].
However, the regulatory role of pro-ANP in CPB is not yet well understood. There are publica-
tions regarding the usefulness of the brain natriuretic peptide in children after cardiac surgery
[26], but there are still no data about the usefulness of pro-ANP in these patients. Brain natri-
uretic peptide and pro-ANP have a good correlation [40] and there exists the possibility to ana-
lyse pro-ANP and pro-ADM together in less than 30 minutes, that supposes an advantage.
Also, pro-ANP could provide additional information in the BNP grey zone and in patients
with obesity, as it was shown in adults [40].
According to our results, cut-off values of pro-ADM and pro-ANP higher than 1.223 nmol/
L and 215.3 pmol/L respectively may indicate a greater affectation of the patient, with greater
need for MV. Thus, early extubation of those patients would have to be carefully evaluated. In
CPB, the classical parameters of early extubation have been surgical times, surgical difficulty
and patients’ severity measured through risk scores such as PRISM III [41–45]. In our study,
both parameters were higher in patients who required MV at admission than in those who did
not. However, the AUC was higher for pro-ADM and pro-ANP than for surgical times or
Table 4. Summary of the biomarker levels according to the length of stay in the pediatric critical care unit at post-CPB1. Date represented as median (interquartile
range) and compared with Mann-Whitney test.
Biomarker levels > 3 days PICU
Yes (n = 42) vs No (n = 21)
p-value > 7 days PICU

















PICU: pediatric intensive care unit; PCT: procalcitonin, pro-ADM: pro-adrenomedullin, pro-ANP: pro-atrial natriuretic peptide.
https://doi.org/10.1371/journal.pone.0215690.t004
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PRISM. In addition, the fact that PRISM III did not correlate either with biomarkers or surgi-
cal times could suggest that this score is influenced by other data not directly related to cardiac
surgery. There are no previous studies that analyse pro-ADM or pro-ANP as useful tools to
determinate a safe early extubation in post-CPB, but our results could be suggestive of that.
The incidence of IBI in children after CPB in this study is similar to previous published
studies [46–49]. PCT was more useful as a diagnostic biomarker of infectious complication
than as a prognostic biomarker. PCT cut-off values were better after 24 hours, as has already
been observed in other studies [12,50,51]. The AUCs were similar to our previous study [50]
and other works such as the one conducted by Aoufi [12]. In that study, a cut-off point for
PCT above 1 ng/ml was a predictor of bacterial infection, and above 10 ng/ml for septic shock.
Furthermore, Jebali found a significant PCT increase in infection cases even at the second
post-operative day [52].
This study has some limitations that should be stated. Firstly, the total number of patients
is relatively low and the results regarding the type of heart disease and type of surgery have
not been analysed, thus it is not possible to know whether the type of surgery may have any
influence. Secondly, this study should be considered as preliminary because of the lack of
similar studies. In view of our results, it would be interesting to carry out a clinical study to
confirm and extent the pro-ADM and pro-ANP value as markers of need for MV after CPB.
An analysis for sub-groups of congenital heart diseases would be valuable to detect possible
confounding factors. If they are suitable markers, biomarker determinations should be
done immediately after CPB in order to decide the best moment for patient extubation, as a
practical tool.
Conclusions
The persistently high values of pro-ADM and pro-ANP after CPB in those patients that needed
MV or inotropic support underline their prognostic usefulness. Pro-ADM and pro-ANP are
good predictors of need for MV and LOS after CPB. A high value of these biomarkers at
admission in PICU after CPB should alert the intensivist not to proceed to an early extubation.
Further investigations are needed to enhance our knowledge about these biomarkers.
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